Nationwide Population-Based Incidence and Survival Rates of Malignant Central Nervous System Germ Cell Tumors in Korea, 2005-2012

Seung Hoon Lee; Kyu-Won Jung; Johyun Ha; Chang-Mo Oh; Hyeseon Kim; Hyeon Jin Park; Heon Yoo; Young-Joo Won

doi:10.4143/crt.2016.129

Articles

Page Path: HOME > Cancer Res Treat > Volume 49(2); 2017 > Article

Original Article Nationwide Population-Based Incidence and Survival Rates of Malignant Central Nervous System Germ Cell Tumors in Korea, 2005-2012: Seung Hoon Lee, MD, PhD^1,2, Kyu-Won Jung, MS³, Johyun Ha, MS³, Chang-Mo Oh, MD, PhD³, Hyeseon Kim, MD¹, Hyeon Jin Park, MD, PhD⁴, Heon Yoo, MD, PhD¹, Young-Joo Won, PhD³; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2017;49(2):494-501.
DOI: https://doi.org/10.4143/crt.2016.129
Published online: August 24, 2016

¹Neuro-Oncology Clinic, National Cancer Center, Goyang, Korea

²Department of Neurosurgery, Eulji University School of Medicine, Daejeon, Korea

³Cancer Registration and Statistics Branch, National Cancer Center, Goyang, Korea

⁴Center for Pediatric Oncology, National Cancer Center, Goyang, Korea

Correspondence: Heon Yoo, MD, PhD Neuro-Oncology Clinic, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-1245 Fax: 82-31-920-1520 E-mail: heonyoo@ncc.re.kr

Co-correspondence: Young-Joo Won, PhD Cancer Registration and Statistics Branch, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-2015 Fax: 82-31-920-2179 E-mail: astra67@ncc.re.kr

^*Seung Hoon Lee and Kyu-Won Jung contributed equally to this work.

• Received: March 25, 2016 • Accepted: August 11, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

13,782 Views
236 Download
36 Web of Science
37 Crossref
41 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Malignant central nervous system (CNS) germ cell tumors (GCTs), although rare, are thought to occur more frequently among Asians. However, a recent population-based study revealed no differences in GCT incidence between Asians and Caucasians. Therefore, this study was conducted to determine the incidence and survival rates of CNS GCTs using the national cancer incidence database, and to compare these rates to those in the United States and Japan.
Materials and Methods
We extracted CNS GCT patients diagnosed between 2005 and 2012 from the Korea Central Cancer Registry database. Age-standardized rates (ASRs), annual percentage change, and the male-female incidence rate ratios (IRRs) were calculated. To estimate the survival rate, we used data for patients diagnosed between 2005 and 2010 and followed their cases until December 31, 2013.
Results
The ASR for CNS GCT between 2005 and 2012 was 0.179 per 100,000 (95% confidence interval, 0.166 to 0.193), with an overall male-to-female (M:F) IRR of 2.95:1. However, when stratified by site, the M:F IRR was 13.62:1 for tumors of the pineal region and 1.87:1 for those located in nonpineal regions. The most frequent histologic type was germinoma (76.0%), and the most frequent location was the suprasellar region (48.5%). The 5-year survival rate of germinoma patients was 95.3%.
Conclusion
The incidence rate of CNS GCTs in Korea during 2005-2012 was 0.179 per 100,000, which was similar to that of the Asian/Pacific Islander subpopulation in the United States. Moreover, the CNS GCT survival rate in Korea was similar to rates in Japan and the United States.
Key words: Central nervous system, Germ cell tumor, Incidence, Survival, Korea

Introduction

Malignant central nervous system (CNS) germ cell tumors (GCTs) are uncommon, accounting for less than 1% of primary brain tumors, and occur predominantly during childhood. The incidence of CNS GCTs has been reported to exhibit a marked association with race, appearing to be more common in Asian countries than in the West [1-13]. However, the majority of previous reports were based on single institution experiences rather than the general population. Recently, a population-based comparison study between Japan and the United States found no significant difference in the incidence of malignant CNS GCTs between these two countries [14]. In contrast, the Central Brian Tumor Registry of the United States (CBTRUS) report published in 2014 stated that Asians/Pacific Islanders (age-standardized rate [ASR], 0.19) were associated with a higher incidence rate of CNS GCTs than Caucasian (ASR, 0.10) and African-American (ASR, 0.07) individuals in the United States [15]. Thus, the existence of racial differences in the incidence of CNS GCT remains unclear.

The aim of this study was to determine the Korean nationwide incidence and survival rate for primary malignant CNS GCTs. Using the Korea Central Cancer Registry (KCCR) database, we reported the precise CNS GCT incidence by age, sex, histological type, and topography in Korea, as well as the survival rate during 2005-2012.

Materials and Methods

1. Data sources

In 1999, the KCCR expanded cancer registration to cover the entire population under the Population-Based Regional Cancer Registry Program [16]. National cancer incidence reports for diseases diagnosed since 1999 began to be published in 2005, and the incidence data for 2012 was 97.7% complete [17]. Data for this study were obtained from the KCCR database.

As GCTs are often malignant, we included only malignant GCTs diagnosed between 2005 and 2012 in this study. We were able to collect more reliable and accurate data describing CNS tumors because, from 2005 onward, information regarding malignant whole-brain and CNS tumors was registered separately from that of benign and borderline tumors. For survival analysis, we included GCTs registered between 2005 and 2010, and followed these cases until December 31, 2013.

GCTs were identified using the International Classification of Diseases for Oncology (third edition), and were selected using the primary sites C70.0-C72.9 and C75.1-C75.3. Tumors were classified into two groups: pineal (C75.3) and nonpineal (C70.0-C72.9 and C75.1-C75.2). Tumors were grouped by histology codes into germinoma (9060, 9061, 9064, and 9065), nongerminomatous GCT (9070, 9071, 9081, 9085, and 9100), and teratoma (9080, 9082, and 9084).

The National Cancer Center Institutional Review Board approved this study (NCC2015-0223). All data were obtained and analyzed after patients were anonymized.

2. Statistical analysis

A total of 654 GCT patients were included in this study. Crude rates were calculated by dividing the total number of cases in a given time period by the entire population, and were expressed per 100,000 persons. ASRs were age-adjusted to the United States population in 2000. Annual percent changes in incidence rates were calculated. The male-to-female (M:F) incidence rate ratios (IRRs) were calculated by dividing the age-adjusted incidence rates of male participants by those of female participants.

For survival analysis, we used only data for patients with tumors that were diagnosed between 2005 and 2010, and excluded cases that could not be followed because of mismatched personal identification numbers and cases in which GCTs were not the primary tumors. Ultimately, 446 newly diagnosed GCT cases were included in survival analysis. The overall 1- to 5-year survival rates of GCT patients, as well as survival by sex, age group, primary site, and histological type were calculated using the life-table method. Survival differences were analyzed by the log-rank test. A p-value < 0.05 indicated statistical significance.

All analyses were conducted using SAS ver. 9.2 (SAS Institute Inc., Cary, NC) and STATA 11.0 (StataCorp LP, College Station, TX).

Results

1. Incidence of GCTs

The KCCR database included 654 cases of primary malignant GCTs of the brain and CNS diagnosed between 2005 and 2012. The annual average number of registered cases was 81.8, and the overall ASR for CNS GCT was 0.179 per 100,000 people (annual percent change, 0.71%; p=0.732) (Table 1). The incidence of all malignant GCTs was significantly higher in male participants (0.263 per 100,000 people; 95% confidence interval [CI], 0.240 to 0.286) than female participants (0.089 per 100,000 people; 95% CI, 0.075 to 0.104). When ranked according to age, the majority of malignant tumors were reported in the young adult (15-29 years, 47.1%) and pediatric (0-14 years, 45.3%) age groups. The pediatric group had the highest incidence rate (0.434 per 100,000 people), followed by the young adult group (0.365) and the adults aged 30 years and over group (0.021).

Approximately 65.4% of GCTs were located outside the pineal region, while the rest were located in the pineal region. The majority (76.0%) of tumors were categorized as germinomas (Table 2).

The overall M:F IRR was 2.95:1. However, when stratified by site, the M:F IRR for pineal region tumors was 13.62:1 compared to an IRR of 1.87:1 for tumors located in a nonpineal region (Table 3).

2. Survival of patients with GCTs

Among the patients with GCT, 46 patients eventually died during the follow-up period. The 5-year observed survival rate was high for all GCTs, at 91.2% (Table 4). These rates showed no statistically significant differences between male and female participants (male participants, 90.9%; female participants, 92.3%; p=0.658) (Fig. 1A), age groups (0-14 years, 90.7%; 15-29 years, 91.8%; 30 years and over, 90.6%; p=0.912) (Fig. 1B), or primary sites (pineal, 91.5%; nonpineal, 91.1%; p=0.843) (Fig. 1C). However, there was a significant difference according to histological type (germinoma, 95.3%; nongerminomatous GCT, 77.6%; teratoma, 76.5%; p < 0.001) (Fig. 1D).

Discussion

The incidence of CNS GCTs is known to be higher in Asia, Japan, and Korea than in other areas of the world. In particular, CNS GCTs account for relatively high proportions of pediatric brain tumors in East Asia, 7.8% in Japan [18], 14.0% in Taiwan [9], 7.9% in China [8], and 9.5% in Korea [19], whereas their frequencies in North America [6,15] and Europe [7,20] are less than 3%. According to the CBTRUS report, the overall incidence of malignant CNS GCTs between 2007 and 2011 was 0.07 per 100,000 in the United States, with the Asian/Pacific Islander group associated with a higher CNS GCT incidence rate (0.19 per 100,000) than Caucasian and African-American participants [15].

In children, the incidences of CNS GCT, including benign tumors, were 0.21 per 100,000 in total and 0.21, 0.14, and 0.51 per 100,000 in Caucasian, African-American, and Asian/ Pacific Islander populations, respectively [15]. Goodwin et al. [21] also described differences in the incidence of pediatric GCTs according to race (Caucasian, 1.29 per 100,000; African-American, 0.33 per 100,000; and Asian, 2.6 per 100,000). Moreover, the childhood incidence of primary CNS GCTs in a regional survey in Kumamoto Prefecture in southern Japan was found to be 0.45 per 100,000 [4]. These data suggest that an Asian genetic background is strongly associated with the development of CNS GCT. However, a recent study demonstrated that the incidence of CNS GCT in Japan was not significantly higher than that in the United States. McCarthy et al. [14] estimated the incidence of malignant CNS GCTs diagnosed during 2004-2006 in 14 population-based registries representing 31.8% of the total population of Japan and analyzed the Surveillance Epidemiology and End Results program database for 17 population-based cancer registries covering 26% of the population of the United States. Unexpectedly, they found the incidence of malignant CNS GCTs in Japan (0.096 per 100,000) to be similar to that in the United States (0.075 per 100,000), and showed the same sex-based patterns by location [14]. The incidence of CNS GCTs in Japan was low compared to those reported in previous studies. These results prompted us to investigate the actual nationwide population-based incidence of CNS GCTs in Korea.

Between 2005 and 2012, 654 cases of newly diagnosed primary malignant CNS GCTs were registered in the KCCR. More than 90% of these tumors were diagnosed with histological confirmation through surgical procedures. The incidence of CNS GCTs in Korea was more than two times higher than that in Japan and the United States. Furthermore, the incidence of pediatric CNS GCTs in Korea (0.434 per 100,000) was similar to the incidence of CNS GCTs in Kumamoto prefecture (0.45 per 100,000). These findings suggest possible geographical variations in CNS GCT incidences in Japan. Kumamoto and Korea may also share a similar genetic background because of their geographical proximity. An international collaborative study would be required to investigate these findings further.

The survival rate of pure germinoma is known to be very high, with the 10-year overall survival rate attaining 90%. For nongerminomatous GCT, the 10-year overall survival rates were reported to be 30%-80% [22]; however, CNS GCTs showed better prognosis among pediatric patients. Matsutani et al. [23] reported that the 10-year survival rates for pure germinoma and mature teratoma were both over 90%. Even though we did not report 10-year survival rates because of our short follow-up period, the survival outcomes observed in this study suggest that CNS GCTs are curable. The 5-year observed survival rate for all patients with CNS GCTs was 91.2%, with no differences observed according to sex, age group, or primary tumor site. However, patients with germinoma showed a greater 5-year survival rate (95.3%) than those with nongerminomatous GCTs (77.6%) and malignant teratomas (76.5%).

It should be noted that our study had some limitations. Specifically, the KCCR does not record cancer risk factors or specific treatment-related factors, making it difficult to determine specific prognostic factors for CNS GCT. Nevertheless, the KCCR data encompasses over 97% of the population of Korea [17], and includes up-to-date information with longer follow-up periods than the data sources used in previous studies. This allows incidence rates to be analyzed with excellent internal validity and generalizability.

Conclusion

In conclusion, our nationwide population-based study revealed that the incidence of CNS GCTs in Korea is significantly higher than the reported incidence for the overall population of the United States, but is comparable to the rate reported for Americans of Asian/Pacific Islander backgrounds.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This work was supported by a research grant from the National Cancer Center (No. 1310220).

Fig. 1.

Cumulative survival curve of germ cell tumors, 2005-2010. (A) Sex. (B) Age group (yr). (C) Primary site. (D) Histological type.

Table 1.

Trends in incidence rate of CNS germ cell tumors, 2005-2012

Year	Case	Incidence rate (per 100,000)
Year	Case	CR	ASR^a)
2005	80	0.164	0.165
2006	86	0.176	0.183
2007	96	0.195	0.209
2008	71	0.144	0.151
2009	85	0.171	0.189
2010	75	0.150	0.166
2011	72	0.144	0.164
2012	89	0.177	0.209
2005-2012	654	0.165	0.179
Annual percent change			0.71% (p=0.732)

CNS, central nervous system; CR, crude rate; ASR, age-standardized rate.

^a) Adjusted with the year 2000 United States standard population.

Table 2.

Germ cell tumor incidence rates, 2005-2012

Group	Total				Male				Female
Group	Case, n (%)	CR	ASR^a)	95% CI	Case, n (%)	CR	ASR^a)	95% CI	Case, n (%)	CR	ASR^a)	95% CI
Total	654 (100.0)	0.165	0.179	0.166-0.193	504 (100.0)	0.254	0.263	0.240-0.286	150 (100.0)	0.076	0.089	0.075-0.104
Age (yr)
0-14	296 (45.3)	0.434	0.093	0.385-0.484	205 (40.7)	0.576	0.124	0.497-0.654	91 (40.7)	0.280	0.060	0.222-0.337
15-29	308 (47.1)	0.365	0.074	0.324-0.406	261 (51.8)	0.594	0.121	0.522-0.667	47 (51.8)	0.116	0.024	0.083-0.149
≥ 30	50 (7.6)	0.021	0.012	0.015-0.026	38 (7.5)	0.032	0.019	0.022-0.042	12 (7.5)	0.010	0.006	0.004-0.015
Primary site
Pineal (C753)	226 (34.6)	0.057	0.062	0.053-0.070	211 (41.9)	0.106	0.111	0.096-0.126	15 (41.9)	0.008	0.008	0.004-0.012
Nonpineal (C700-729, 751-752)	428 (65.4)	0.108	0.118	0.107-0.129	293 (58.1)	0.148	0.152	0.134-0.170	135 (58.1)	0.068	0.081	0.067-0.095
Suprasellar region (C715, 719, 729, 751)	317 (48.5)	0.080	0.087	0.078-0.097	204 (40.5)	0.103	0.105	0.091-0.120	113 (40.5)	0.057	0.068	0.055-0.081
Ventricle (C715)	43 (6.6)	0.011	0.012	0.008-0.015	35 (6.9)	0.018	0.018	0.012-0.024	8 (6.9)	0.004	0.005	0.002-0.009
Brain, NOS (C719)	229 (35.0)	0.058	0.064	0.056-0.072	145 (28.8)	0.073	0.075	0.063-0.088	84 (28.8)	0.042	0.052	0.040-0.063
Nervous system, NOS (C729)	1 (0.2)	0.000	0.000	0.000-0.001	1 (0.2)	0.001	0.001	–0.001-0.002	0 (0.2)	-	-	-
Pituitary gland (C751)	44 (6.7)	0.011	0.011	0.008-0.015	23 (4.6)	0.012	0.011	0.007-0.016	21 (4.6)	0.011	0.011	0.006-0.016
Cerebrum (C710)	62 (9.5)	0.016	0.017	0.013-0.022	53 (10.5)	0.027	0.029	0.021-0.037	9 (10.5)	0.005	0.005	0.002-0.009
All other sites	49 (7.5)	0.012	0.013	0.009-0.017	36 (7.1)	0.018	0.018	0.012-0.024	13 (7.1)	0.007	0.008	0.004-0.012
Histology
Germinoma	497 (76.0)	0.125	0.134	0.122-0.146	385 (76.4)	0.194	0.197	0.177-0.217	112 (76.4)	0.057	0.066	0.053-0.078
Nongerminomatous GCT	116 (17.7)	0.029	0.034	0.027-0.040	85 (16.9)	0.043	0.047	0.037-0.057	31 (16.9)	0.016	0.019	0.012-0.026
Nongerminomatous excluding mixed germ cell	26 (4.0)	0.007	0.008	0.005-0.010	20 (4.0)	0.010	0.011	0.006-0.016	6 (4.0)	0.003	0.004	0.001-0.006
Mixed germ cell	90 (13.8)	0.023	0.026	0.021-0.031	65 (12.9)	0.033	0.036	0.027-0.044	25 (12.9)	0.013	0.016	0.010-0.022
Teratoma	41 (6.3)	0.010	0.012	0.008-0.016	34 (6.7)	0.017	0.019	0.013-0.026	7 (6.7)	0.004	0.004	0.001-0.007

CR, crude rate; ASR, age-standardized rate; CI, confidence interval; NOS, not otherwise specified; GCT, germ cell tumor.

^a) Adjusted with the year 2000 United States standard population.

Table 3.

Germ cell tumor male-female incidence rate ratio, 2005-2012

Primary site	Total		Male		Female		Male to female rate ratio (95% CI)
Primary site	Count, n (%)	ASR^a)	Count, n (%)	ASR^a)	Count, n (%)	ASR^a)	Male to female rate ratio (95% CI)
Pineal (C753)	226 (34.6)	0.06	211 (42.0)	0.11	15 (10.0)	0.01	13.62 (9.15-20.28)
Nonpineal (C700-729, 751-752)	428 (65.4)	0.12	293 (58.1)	0.15	135 (90.0)	0.08	1.87 (1.54-2.28)
Suprasellar region (C715, 719, 729, 751)	317 (48.5)	0.09	204 (40.5)	0.11	113 (75.3)	0.07	1.55 (1.23-1.94)
Ventricle (C715)	43 (6.6)	0.01	35 (6.9)	0.02	8 (5.3)	0.01	3.52 (1.78-6.97)
Brain, NOS (C719)	229 (35.0)	0.06	145 (28.8)	0.08	84 (56.0)	0.05	1.46 (1.12-1.91)
Nervous system, NOS (C729)	1 (0.2)	0.00	1 (0.2)	0.00	0	0.00	0.00 (0.00-0.00)
Pituitary gland (C751)	44 (6.7)	0.01	23 (4.6)	0.01	21 (14.0)	0.01	0.99 (0.54-1.79)
Cerebrum (C710)	62 (9.5)	0.02	53 (10.5)	0.03	9 (6.0)	0.01	5.45 (2.94-10.09)
All other sites	49 (7.5)	0.01	36 (7.1)	0.02	13 (8.7)	0.01	2.31 (1.27-4.20)
All germ cell tumors	654 (100.0)	0.18	504 (100.0)	0.26	150 (100.0)	0.09	2.95 (2.49-3.49)

ASR, age-standardized rate; CI, confidence interval; NOS, not otherwise specified.

^a) Adjusted with the year 2000 United States standard population.

Table 4.

Survival rate of germ cell tumors, 2005-2010

Characteristic	Case, n (%)	Observed survival rate (%)
Characteristic	Case, n (%)	1-Year	2-Year	3-Year	4-Year	5-Year
Total	446 (100.0)	94.8	93.3	91.7	91.2	91.2
Sex
Male	342 (76.7)	94.7	92.7	91.5	90.9	90.9
Female	104 (23.3)	95.2	95.2	92.3	92.3	92.3
Age group (yr)
0-14	205 (46.0)	93.7	92.2	90.7	90.7	90.7
15-29	209 (46.9)	95.7	93.8	92.8	91.8	91.8
≥ 30	32 (7.2)	96.9	96.9	90.6	90.6	90.6
Primary site
Pineal (C753)	142 (31.8)	97.2	94.4	92.3	91.5	91.5
Nonpineal (C700-C729, 751-752)	304 (68.2)	93.8	92.8	91.4	91.1	91.1
Histology
Germinoma	344 (77.1)	97.1	96.5	95.3	95.3	95.3
Nongerminomatous germ cell tumor	72 (16.1)	88.9	81.9	79.2	77.6	77.6
Nongerminomatous excluding mixed germ cell	17 (3.8)	82.4	70.6	70.6	70.6	70.6
Mixed germ cell	55 (12.3)	90.9	85.5	81.8	79.8	79.8
Teratoma	30 (6.7)	83.3	83.3	80.0	76.5	76.5

REFERENCES

1. Villano JL, Propp JM, Porter KR, Stewart AK, Valyi-Nagy T, Li X, et al. Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries. Neuro Oncol. 2008;10:121–30. Article PubMed PMC
2. Thakkar JP, Chew L, Villano JL. Primary CNS germ cell tumors: current epidemiology and update on treatment. Med Oncol. 2013;30:496.Article PubMed
3. Oi S, Matsuzawa K, Choi JU, Kim DS, Kang JK, Cho BK. Identical characteristics of the patient populations with pineal region tumors in Japan and in Korea and therapeutic modalities. Childs Nerv Syst. 1998;14:36–40. Article PubMed
4. Makino K, Nakamura H, Yano S, Kuratsu J; Kumamoto Brain Tumor Research Group. Incidence of primary central nervous system germ cell tumors in childhood: a regional survey in Kumamoto prefecture in southern Japan. Pediatr Neurosurg. 2013;49:155–8. Article PubMed
5. Kuratsu J, Takeshima H, Ushio Y. Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int J Clin Oncol. 2001;6:183–91. Article PubMed PDF
6. Keene D, Johnston D, Strother D, Fryer C, Carret AS, Crooks B, et al. Epidemiological survey of central nervous system germ cell tumors in Canadian children. J Neurooncol. 2007;82:289–95. Article PubMed
7. Kaatsch P, Rickert CH, Kuhl J, Schuz J, Michaelis J. Population-based epidemiologic data on brain tumors in German children. Cancer. 2001;92:3155–64. Article PubMed
8. Zhou D, Zhang Y, Liu H, Luo S, Luo L, Dai K. Epidemiology of nervous system tumors in children: a survey of 1,485 cases in Beijing Tiantan Hospital from 2001 to 2005. Pediatr Neurosurg. 2008;44:97–103. Article PubMed
9. Wong TT, Ho DM, Chang KP, Yen SH, Guo WY, Chang FC, et al. Primary pediatric brain tumors: statistics of Taipei VGH, Taiwan (1975-2004). Cancer. 2005;104:2156–67. Article PubMed
10. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001;17:503–11. Article PubMed
11. Nomura K. Epidemiology of germ cell tumors in Asia of pineal region tumor. J Neurooncol. 2001;54:211–7. Article PubMed
12. Kaneko S, Nomura K, Yoshimura T, Yamaguchi N. Trend of brain tumor incidence by histological subtypes in Japan: estimation from the Brain Tumor Registry of Japan, 1973-1993. J Neurooncol. 2002;60:61–9. Article PubMed
13. Cho KT, Wang KC, Kim SK, Shin SH, Chi JG, Cho BK. Pediatric brain tumors: statistics of SNUH, Korea (1959-2000). Childs Nerv Syst. 2002;18:30–7. Article PubMed
14. McCarthy BJ, Shibui S, Kayama T, Miyaoka E, Narita Y, Murakami M, et al. Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries. Neuro Oncol. 2012;14:1194–200. Article PubMed PMC
15. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16 Suppl 4:iv1–63. Article PubMed PMC
16. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001: first result using the national cancer incidence database. Cancer Res Treat. 2005;37:325–31. Article PubMed PMC PDF
17. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41. Article PubMed PMC PDF
18. Mori K, Kurisaka M. Brain tumors in childhood: statistical analysis of cases from the Brain Tumor Registry of Japan. Childs Nerv Syst. 1986;2:233–7. Article PubMed PDF
19. Jung KW, Ha J, Lee SH, Won YJ, Yoo H. An updated nationwide epidemiology of primary brain tumors in republic of Korea. Brain Tumor Res Treat. 2013;1:16–23. Article PubMed PMC
20. Bailey S, Skinner R, Lucraft HH, Perry RH, Todd N, Pearson AD. Pineal tumours in the north of England 1968-93. Arch Dis Child. 1996;75:181–5. Article PubMed PMC
21. Goodwin TL, Sainani K, Fisher PG. Incidence patterns of central nervous system germ cell tumors: a SEER Study. J Pediatr Hematol Oncol. 2009;31:541–4. Article PubMed
22. Kim JY, Park J. Understanding the treatment strategies of intracranial germ cell tumors: focusing on radiotherapy. J Korean Neurosurg Soc. 2015;57:315–22. Article PubMed PMC
23. Matsutani M. Combined chemotherapy and radiation therapy for CNS germ cell tumors: the Japanese experience. J Neurooncol. 2001;54:311–6. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Dosimetric impacts on height development after radiotherapy for intracranial non-germinomatous germ cell tumors
Guanhua Deng, Juan Li, Zhaoming Zhou, Changguo Shan, Jing He, Mingyao Lai, Ping Zhang, Junjie Zhen, Shaoqun Li, Weiping Hong, Xiaolei Hu, Jie Ding, Linbo Cai, Cheng Zhou, Lei Wen
International Journal of Radiation Biology.2025; 101(5): 510. CrossRef
A novel perspective on dissemination: somatic metastasis of germ cell tumors from the central nervous system
Shao-Pei Qi, Chuan Zhao, Jing-Jing Ge, Cheng Li, Feng-Jun Xue, Chi Zhao, Chen-Chen Kong, Hui-Jie Sun, Jing-Jing Zhang, Ya-Qi Zhang, Jun-Ping Zhang
Discover Oncology.2025;[Epub] CrossRef
Development and validation of a nomogram for predicting overall survival in patients with primary central nervous system germ cell tumors
Dunchen Yao, Baokui Ye, Hongli Zhang, Long Pan, Dongjie Yao, Xu Li, Chengcheng Guo
Frontiers in Immunology.2025;[Epub] CrossRef
Global population-based childhood cancer survival in the 21st century: a scoping review
Charles A. Stiller
Frontiers in Cancer Control and Society.2025;[Epub] CrossRef
Pediatric sellar teratoma – Case report and review of the literature
Katja Kürner, Ladina Greuter, Michel Roethlisberger, Yves Brand, Stephan Frank, Raphael Guzman, Jehuda Soleman
Child's Nervous System.2024; 40(4): 1259. CrossRef
Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities
Bo Li, Shuang Zhao, Shouwei Li, Chunde Li, Wei Liu, Lin Li, Bowen Cui, Xing Liu, Huiyuan Chen, Jing Zhang, Yin Ren, Fei Liu, Ming Yang, Tao Jiang, Yu Liu, Xiaoguang Qiu
Neuro-Oncology.2024; 26(7): 1335. CrossRef
Effect of delayed diagnosis on neuroendocrine function in individuals with suprasellar germ cell tumors
Tao Tong, Jian Xu, Han Chen, Caiyan Mo, Dan Liang, Liyong Zhong
Frontiers in Endocrinology.2024;[Epub] CrossRef
A deep learning model for differentiating paediatric intracranial germ cell tumour subtypes and predicting survival with MRI: a multicentre prospective study
Yanong Li, Zhizheng Zhuo, Jinyuan Weng, Sven Haller, Harrison X. Bai, Bo Li, Xing Liu, Mingwang Zhu, Zheng Wang, Jane Li, Xiaoguang Qiu, Yaou Liu
BMC Medicine.2024;[Epub] CrossRef
High detection rate of circulating-tumor DNA from cerebrospinal fluid of children with central nervous system germ cell tumors
Yoshiko Nakano, Ian Burns, Liana Nobre, Robert Siddaway, Mansuba Rana, Cody Nesvick, Andrew Bondoc, Michelle Ku, Richard Yuditskiy, Dennis T. L. Ku, Matthew M. K. Shing, Kevin K. F. Cheng, Ho-Keung Ng, Anirban Das, Julie Bennett, Vijay Ramaswamy, Annie Hu
Acta Neuropathologica Communications.2024;[Epub] CrossRef
The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis
Nader Salari, Hooman Ghasemi, Reza Fatahian, Kamran Mansouri, Sadat Dokaneheifard, Mohammad hossain Shiri, Mahvan Hemmati, Masoud Mohammadi
European Journal of Medical Research.2023;[Epub] CrossRef
Intracranial Germinomas: Diagnosis, Pathogenesis, Clinical Presentation, and Management
Natalia Kremenevski, Michael Buchfelder, Nirjhar Hore
Current Oncology Reports.2023; 25(7): 765. CrossRef
Diagnostik der Keimzelltumoren
Armin Bachhuber
Die Radiologie.2023; 63(8): 598. CrossRef
Methionine metabolism and endocrine function of the pituitary gland in patients with suprasellar germinoma
Hwanhee Lee, Ji Won Lee, Hee Won Cho, Yearn Seong Choe, Kyung-Han Lee, Joon Young Choi, Ki Woong Sung, Seung Hwan Moon, Liza Das
PLOS ONE.2023; 18(7): e0288528. CrossRef
The role of neoadjuvant chemotherapy in the management of metastatic central nervous system germinoma: A meta‐analysis
Mohammad H. Abu‐Arja, Margaret S. Shatara, M. Fatih Okcu, Susan L. McGovern, Jack M. Su, Mohamed S. Abdelbaki
Pediatric Blood & Cancer.2023;[Epub] CrossRef
Treatment outcomes for response-based radiotherapy in children and adolescents with central nervous system germinoma: a prospective study
Chenggong Zeng, Qunying Yang, Zhuoran Li, Zhiqing Wei, Tingting Chen, Meiling Deng, Jian Wang, Juan Wang, Feifei Sun, Junting Huang, Suying Lu, Jia Zhu, Xiaofei Sun, Zijun Zhen
Journal of Neuro-Oncology.2023; 164(3): 643. CrossRef
Intracranial Germ Cell Tumors
Teri Danielle You Ying Yeoh, Vincent Nga, Miriam Kimpo, Simon S. Lo, Balamurugan Vellayappan
Seminars in Neurology.2023; 43(06): 897. CrossRef
A Pineal Germinoma with Rapid Enlargement following Tumor Resection
Chia-Jung Hsu, Hsiang-Chih Liao, Dueng-Yuan Hueng, Kuan-Yin Tseng
Diagnostics.2023; 13(23): 3579. CrossRef
Survival outcomes, hematologic complications and growth impairment after sequential chemoradiotherapy in intracranial NGGCTs: a retrospective study
Lei Wen, Juan Li, Mingyao Lai, Zhaoming Zhou, Qingjun Hu, Guanhua Deng, Changguo Shan, Ruyu Ai, Hainan Li, Ming Lu, Liang Zhang, Taihua Wu, Dan Zhu, Yuanyuan Chen, Longhua Chen, Linbo Cai, Cheng Zhou
Strahlentherapie und Onkologie.2022; 198(5): 458. CrossRef
Depression, anxiety and health-related quality of life in paediatric intracranial germ cell tumor survivors
Wenyi Lv, Bo Li, Jin Feng, Li Chen, Xiaoguang Qiu, Shuai Liu
Health and Quality of Life Outcomes.2022;[Epub] CrossRef
Hypothalamic syndrome
Hermann L. Müller, Maithé Tauber, Elizabeth A. Lawson, Jale Özyurt, Brigitte Bison, Juan-Pedro Martinez-Barbera, Stephanie Puget, Thomas E. Merchant, Hanneke M. van Santen
Nature Reviews Disease Primers.2022;[Epub] CrossRef
A GIANT GERMINOMA MIMICS HIGH-GRADE GLIOMA: A RARE FORM OF THALAMIC REGION TUMOR
Dirga Rachmad Aprianto, Muhammad Arifin Parenrengi
Wiadomości Lekarskie.2022; 75(8): 2036. CrossRef
Clinical Outcomes and Diagnostic Consistency of Serum and CSF Tumor Markers in Pediatric Intracranial Germ Cell Tumors in Thailand: A Multicenter Study
Lalita Sathitsamitphong, Chalinee Monsereenusorn, Piti Techavichit, Kanjana Shotelersuk, Piradee Suwanpakdee, Piya Rujkijyanont, Pimlak Charoenkwan
Global Pediatric Health.2022;[Epub] CrossRef
Neurological and endocrinological manifestations of 49 children with intracranial pure germinoma at initial diagnosis in Taiwan
Hsin-Yuan Chang, Chiao-Fan Chiu, Shih-Ming Jung, Alex Mun-Ching Wong, Chieh-Tsai Wu, Fu-Sung Lo
Pediatrics & Neonatology.2021; 62(1): 106. CrossRef
Management trends and outcomes of pineal germinoma in a multi-institutional Australian cohort
Sean Stephens, Anna Kuchel, Robyn Cheuk, Hamish Alexander, Thomas Robertson, Thulasi Rajah, Quan Tran, Po-ling Inglis
Journal of Clinical Neuroscience.2021; 90: 1. CrossRef
Characteristics of growth disturbances in patients with intracranial germinomas of different origins
Bo Li, Jiayi Wang, Jiongxian Yang, Yanong Li, Yanwei Liu, Shuai Liu, Xiaoguang Qiu
Child's Nervous System.2021; 37(8): 2531. CrossRef
A clinical approach to parasellar lesions in the transition age
Emilia Sbardella, Giulia Puliani, Tiziana Feola, Riccardo Pofi, Rosa Pirchio, Franz Sesti, Federica Verdecchia, Daniele Gianfrilli, Daniel Moffat, Andrea M. Isidori, Ashley B. Grossman
Journal of Neuroendocrinology.2021;[Epub] CrossRef
Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999–2017
Meerim Park, Jiwon Lim, Jun Ah Lee, Hyeon Jin Park, Byung Kiu Park, Myong Cheol Lim, Sang-Yoon Park, Young-Joo Won
Gynecologic Oncology.2021; 163(1): 79. CrossRef
Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae
Joo Ho Lee, Keun-Yong Eom, Ji Hoon Phi, Chul-Kee Park, Seung Ki Kim, Byung-Kyu Cho, Tae Min Kim, Dae Seog Heo, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Hee Young Shin, Seung Hong Choi, Soon Tae Lee, Sung Hye Park, Kyu-Chang Wang, Il Han Kim
Cancer Research and Treatment.2021; 53(4): 983. CrossRef
Diagnostic Capability of Cerebrospinal Fluid-Placental Alkaline Phosphatase Value in Intracranial Germ Cell Tumor
Michinari Okamoto, Shigeru Yamaguchi, Yukitomo Ishi, Hiroaki Motegi, Takashi Mori, Takayuki Hashimoto, Yukayo Terashita, Shinsuke Hirabayashi, Minako Sugiyama, Akihiro Iguchi, Yuko Cho, Atsushi Manabe, Kiyohiro Houkin
Oncology.2021; 99(1): 23. CrossRef
Symptom interval and treatment burden for patients with malignant central nervous system germ cell tumours
James Hayden, Matthew J Murray, Ute Bartels, Thankamma Ajithkumar, Brinda Muthusamy, Anthony Penn, Gabriele Calaminus, James Nicholson
Archives of Disease in Childhood.2020; 105(3): 247. CrossRef
Study Progress of Intracranial Germ Cell Tumors
晓红高
Advances in Clinical Medicine.2020; 10(03): 270. CrossRef
Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors
Takeshi Takayasu, Mauli Shah, Antonio Dono, Yuanqing Yan, Roshan Borkar, Nagireddy Putluri, Jay-Jiguang Zhu, Seiji Hama, Fumiyuki Yamasaki, Hidetoshi Tahara, Kazuhiko Sugiyama, Kaoru Kurisu, Yoshua Esquenazi, Leomar Y. Ballester
Scientific Reports.2020;[Epub] CrossRef
Canadian Pediatric Neuro-Oncology Standards of Practice
Julie Bennett, Craig Erker, Lucie Lafay-Cousin, Vijay Ramaswamy, Juliette Hukin, Magimairajan I. Vanan, Sylvia Cheng, Hallie Coltin, Adriana Fonseca, Donna Johnston, Andrea Lo, Shayna Zelcer, Saima Alvi, Lynette Bowes, Josée Brossard, Janie Charlebois, Da
Frontiers in Oncology.2020;[Epub] CrossRef
Critical review of the management of primary central nervous nongerminomatous germ cell tumors
Mohammad H. Abu Arja, Eric Bouffet, Jonathan L. Finlay, Mohamed S. AbdelBaki
Pediatric Blood & Cancer.2019;[Epub] CrossRef
Emergency irradiation of 3.4Gy/2f in pineal gland germinoma patients with symptomatic hydrocephalus
Bo Li, Youqi Li, Chunde Li, Yanwei Liu, Shuai Liu, Xiaoguang Qiu, Shiqi Luo
Chinese Neurosurgical Journal.2019;[Epub] CrossRef
A Nationwide, Population-Based Epidemiologic Study of Childhood Brain Tumors in Korea, 2005–2014: A Comparison with United States Data
Ji-Man Kang, Johyun Ha, Eun Kyung Hong, Hee Young Ju, Byung Kiu Park, Sang-Hoon Shin, Young-Joo Won, Kyu-Won Jung, Hyeon Jin Park
Cancer Epidemiology, Biomarkers & Prevention.2019; 28(2): 409. CrossRef
Central Nervous System Germ Cell Tumors: A Review of the Literature
Ziren Kong, Yaning Wang, Congxin Dai, Yong Yao, Wenbin Ma, Yu Wang
Journal of Child Neurology.2018; 33(9): 610. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Nationwide Population-Based Incidence and Survival Rates of Malignant Central Nervous System Germ Cell Tumors in Korea, 2005-2012

Cancer Res Treat. 2017;49(2):494-501. Published online August 24, 2016

DOI: https://doi.org/10.4143/crt.2016.129

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Nationwide Population-Based Incidence and Survival Rates of Malignant Central Nervous System Germ Cell Tumors in Korea, 2005-2012

Fig. 1. Cumulative survival curve of germ cell tumors, 2005-2010. (A) Sex. (B) Age group (yr). (C) Primary site. (D) Histological type.

Fig. 1.

Nationwide Population-Based Incidence and Survival Rates of Malignant Central Nervous System Germ Cell Tumors in Korea, 2005-2012

Year	Case	Incidence rate (per 100,000)
Year	Case	CR	ASR^a)
2005	80	0.164	0.165
2006	86	0.176	0.183
2007	96	0.195	0.209
2008	71	0.144	0.151
2009	85	0.171	0.189
2010	75	0.150	0.166
2011	72	0.144	0.164
2012	89	0.177	0.209
2005-2012	654	0.165	0.179
Annual percent change			0.71% (p=0.732)

Group	Total				Male				Female
Group	Case, n (%)	CR	ASR^a)	95% CI	Case, n (%)	CR	ASR^a)	95% CI	Case, n (%)	CR	ASR^a)	95% CI
Total	654 (100.0)	0.165	0.179	0.166-0.193	504 (100.0)	0.254	0.263	0.240-0.286	150 (100.0)	0.076	0.089	0.075-0.104
Age (yr)
0-14	296 (45.3)	0.434	0.093	0.385-0.484	205 (40.7)	0.576	0.124	0.497-0.654	91 (40.7)	0.280	0.060	0.222-0.337
15-29	308 (47.1)	0.365	0.074	0.324-0.406	261 (51.8)	0.594	0.121	0.522-0.667	47 (51.8)	0.116	0.024	0.083-0.149
≥ 30	50 (7.6)	0.021	0.012	0.015-0.026	38 (7.5)	0.032	0.019	0.022-0.042	12 (7.5)	0.010	0.006	0.004-0.015
Primary site
Pineal (C753)	226 (34.6)	0.057	0.062	0.053-0.070	211 (41.9)	0.106	0.111	0.096-0.126	15 (41.9)	0.008	0.008	0.004-0.012
Nonpineal (C700-729, 751-752)	428 (65.4)	0.108	0.118	0.107-0.129	293 (58.1)	0.148	0.152	0.134-0.170	135 (58.1)	0.068	0.081	0.067-0.095
Suprasellar region (C715, 719, 729, 751)	317 (48.5)	0.080	0.087	0.078-0.097	204 (40.5)	0.103	0.105	0.091-0.120	113 (40.5)	0.057	0.068	0.055-0.081
Ventricle (C715)	43 (6.6)	0.011	0.012	0.008-0.015	35 (6.9)	0.018	0.018	0.012-0.024	8 (6.9)	0.004	0.005	0.002-0.009
Brain, NOS (C719)	229 (35.0)	0.058	0.064	0.056-0.072	145 (28.8)	0.073	0.075	0.063-0.088	84 (28.8)	0.042	0.052	0.040-0.063
Nervous system, NOS (C729)	1 (0.2)	0.000	0.000	0.000-0.001	1 (0.2)	0.001	0.001	–0.001-0.002	0 (0.2)	-	-	-
Pituitary gland (C751)	44 (6.7)	0.011	0.011	0.008-0.015	23 (4.6)	0.012	0.011	0.007-0.016	21 (4.6)	0.011	0.011	0.006-0.016
Cerebrum (C710)	62 (9.5)	0.016	0.017	0.013-0.022	53 (10.5)	0.027	0.029	0.021-0.037	9 (10.5)	0.005	0.005	0.002-0.009
All other sites	49 (7.5)	0.012	0.013	0.009-0.017	36 (7.1)	0.018	0.018	0.012-0.024	13 (7.1)	0.007	0.008	0.004-0.012
Histology
Germinoma	497 (76.0)	0.125	0.134	0.122-0.146	385 (76.4)	0.194	0.197	0.177-0.217	112 (76.4)	0.057	0.066	0.053-0.078
Nongerminomatous GCT	116 (17.7)	0.029	0.034	0.027-0.040	85 (16.9)	0.043	0.047	0.037-0.057	31 (16.9)	0.016	0.019	0.012-0.026
Nongerminomatous excluding mixed germ cell	26 (4.0)	0.007	0.008	0.005-0.010	20 (4.0)	0.010	0.011	0.006-0.016	6 (4.0)	0.003	0.004	0.001-0.006
Mixed germ cell	90 (13.8)	0.023	0.026	0.021-0.031	65 (12.9)	0.033	0.036	0.027-0.044	25 (12.9)	0.013	0.016	0.010-0.022
Teratoma	41 (6.3)	0.010	0.012	0.008-0.016	34 (6.7)	0.017	0.019	0.013-0.026	7 (6.7)	0.004	0.004	0.001-0.007

Primary site	Total		Male		Female		Male to female rate ratio (95% CI)
Primary site	Count, n (%)	ASR^a)	Count, n (%)	ASR^a)	Count, n (%)	ASR^a)	Male to female rate ratio (95% CI)
Pineal (C753)	226 (34.6)	0.06	211 (42.0)	0.11	15 (10.0)	0.01	13.62 (9.15-20.28)
Nonpineal (C700-729, 751-752)	428 (65.4)	0.12	293 (58.1)	0.15	135 (90.0)	0.08	1.87 (1.54-2.28)
Suprasellar region (C715, 719, 729, 751)	317 (48.5)	0.09	204 (40.5)	0.11	113 (75.3)	0.07	1.55 (1.23-1.94)
Ventricle (C715)	43 (6.6)	0.01	35 (6.9)	0.02	8 (5.3)	0.01	3.52 (1.78-6.97)
Brain, NOS (C719)	229 (35.0)	0.06	145 (28.8)	0.08	84 (56.0)	0.05	1.46 (1.12-1.91)
Nervous system, NOS (C729)	1 (0.2)	0.00	1 (0.2)	0.00	0	0.00	0.00 (0.00-0.00)
Pituitary gland (C751)	44 (6.7)	0.01	23 (4.6)	0.01	21 (14.0)	0.01	0.99 (0.54-1.79)
Cerebrum (C710)	62 (9.5)	0.02	53 (10.5)	0.03	9 (6.0)	0.01	5.45 (2.94-10.09)
All other sites	49 (7.5)	0.01	36 (7.1)	0.02	13 (8.7)	0.01	2.31 (1.27-4.20)
All germ cell tumors	654 (100.0)	0.18	504 (100.0)	0.26	150 (100.0)	0.09	2.95 (2.49-3.49)

Characteristic	Case, n (%)	Observed survival rate (%)
Characteristic	Case, n (%)	1-Year	2-Year	3-Year	4-Year	5-Year
Total	446 (100.0)	94.8	93.3	91.7	91.2	91.2
Sex
Male	342 (76.7)	94.7	92.7	91.5	90.9	90.9
Female	104 (23.3)	95.2	95.2	92.3	92.3	92.3
Age group (yr)
0-14	205 (46.0)	93.7	92.2	90.7	90.7	90.7
15-29	209 (46.9)	95.7	93.8	92.8	91.8	91.8
≥ 30	32 (7.2)	96.9	96.9	90.6	90.6	90.6
Primary site
Pineal (C753)	142 (31.8)	97.2	94.4	92.3	91.5	91.5
Nonpineal (C700-C729, 751-752)	304 (68.2)	93.8	92.8	91.4	91.1	91.1
Histology
Germinoma	344 (77.1)	97.1	96.5	95.3	95.3	95.3
Nongerminomatous germ cell tumor	72 (16.1)	88.9	81.9	79.2	77.6	77.6
Nongerminomatous excluding mixed germ cell	17 (3.8)	82.4	70.6	70.6	70.6	70.6
Mixed germ cell	55 (12.3)	90.9	85.5	81.8	79.8	79.8
Teratoma	30 (6.7)	83.3	83.3	80.0	76.5	76.5

Table 1. Trends in incidence rate of CNS germ cell tumors, 2005-2012

CNS, central nervous system; CR, crude rate; ASR, age-standardized rate.

Adjusted with the year 2000 United States standard population.

Table 2. Germ cell tumor incidence rates, 2005-2012

CR, crude rate; ASR, age-standardized rate; CI, confidence interval; NOS, not otherwise specified; GCT, germ cell tumor.

Adjusted with the year 2000 United States standard population.

Table 3. Germ cell tumor male-female incidence rate ratio, 2005-2012

ASR, age-standardized rate; CI, confidence interval; NOS, not otherwise specified.

Adjusted with the year 2000 United States standard population.

Table 4. Survival rate of germ cell tumors, 2005-2010